Remus Pharmaceuticals Limited

NSE: REMUS · Unclassified

₹800.45-4.69%06 Nov 2026

Ask the data

Instant answers about Remus Pharmaceuticals Limited — computed from its filings, no language model

Market cap₹943 cr

Current price₹800.45

High / Low₹1,021 / ₹583

P/E25.5

P/B2.69

Book value₹298.0

ROE10.5%

ROCE16.2%

Debt / equity0.07

Dividend yield0.13%

EPS (TTM)₹31.40

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY24	FY25	FY26
Revenue	212.5	620.4	853.6
EBITDA	27.8	45.7	56.7
Operating margin	13.1%	7.4%	6.6%
Interest	0.5	1.5	1.5
Depreciation	0.9	1.9	2.8
Profit before tax	31.8	47.3	59.2
Tax	5.8	8.9	13.0
Net profit	21.5	29.1	37.0
EPS ₹	152.01	65.21	39.19
Operating cash flow	3.6	7.0	18.2
Capex	0.6	4.0	14.6
Dividend paid	0.6	1.2	1.2
Total assets	—	432.6	578.6
Equity	—	255.9	351.0

Half-yearly performance

last 6 half years · ₹ crore

	H1 FY24	H2 FY24	H1 FY25	H2 FY25	H1 FY26	H2 FY26
Revenue	29.0	183.5	272.7	347.8	400.2	453.4
Operating profit	9.3	18.5	20.5	24.5	26.9	29.8
Operating margin	31.9%	10.1%	7.5%	7.1%	6.7%	6.6%
Other income	1.7	3.7	2.9	2.6	2.9	3.8
Interest	0.1	0.4	0.7	0.6	0.7	0.8
Depreciation	0.4	0.5	0.4	1.2	1.3	1.5
Profit before tax	10.4	23.6	22.3	25.4	27.9	31.3
Tax	2.6	3.2	3.5	4.8	6.3	6.7
Net profit	5.7	15.9	14.0	16.0	17.5	19.5
EPS ₹	41.51	110.50	23.78	34.92	18.33	20.86
Revenue YoY	—	—	839.0%	89.6%	46.8%	30.4%
Profit YoY	—	—	148.0%	0.8%	24.9%	21.7%

Returns & margins

trailing-twelve-month, per half year

	H2 FY24	H1 FY25	H2 FY25	H1 FY26	H2 FY26
ROE	—	29.8%	11.7%	10.9%	10.5%
ROCE	—	38.7%	17.7%	17.0%	16.2%
Net margin	10.1%	6.6%	4.8%	4.5%	4.3%
EBITDA margin	13.1%	8.6%	7.3%	6.9%	6.6%
Debt / equity	—	0.21	0.08	0.05	0.07
Interest coverage	70.37	42.31	36.01	42.28	41.24
Asset turnover	—	2.06	1.43	1.32	1.48

Balance sheet

equity vs borrowings over time · ₹ crore

	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	5.9	5.9	11.8	11.8
Other equity / reserves	94.6	250.0	295.2	339.2
Total equity	100.5	255.9	307.0	351.0
Borrowings	20.8	20.8	14.1	23.0
Current liabilities	94.3	121.5	194.9	149.1
Non-current liabilities	4.2	28.6	35.3	41.8
Total assets	221.4	432.6	568.2	578.6
Property, plant & equipment	3.6	6.8	8.8	5.7
Capital work-in-progress	—	0.0	0.2	8.3
Investments	20.6	186.1	237.6	274.6
Inventories	37.9	51.6	105.5	72.1
Receivables	59.7	108.0	147.7	139.8
Cash & equivalents	46.0	7.2	6.7	11.8

Cash flow

annual · ₹ crore · line = free cash flow

	FY24	FY25	FY26
Cash from operations	3.6	7.0	18.2
Cash from investing	-8.9	-10.6	-15.0
Cash from financing	24.4	6.1	1.4
Capex	0.6	4.0	14.6
Free cash flow	3.0	3.0	3.6
Dividends paid	0.6	1.2	1.2

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹5.7 cr1%

CWIP

₹8.3 cr1%

Investments

₹274.6 cr47%

Inventories

₹72.1 cr12%

Receivables

₹139.8 cr24%

Cash & equivalents

₹11.8 cr2%

Other assets

₹66.4 cr11%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Remus Pharmaceuticals Limited	943	800.45	25.5	2.69	10.5%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-6.5%

6 months+7.2%

1 year+18.8%

3Y CAGR-34.6%

5Y CAGR—

10Y CAGR—

50-day avg₹907.38

200-day avg₹766.35

RSI (14)16

FAQs

What is the share price of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited (REMUS) closed at ₹800.45 on NSE on 06 Nov 2026.

What is the market cap of Remus Pharmaceuticals Limited?

₹943 crore at the latest close.

What is the P/E ratio of Remus Pharmaceuticals Limited?

25.5, on trailing-twelve-month earnings from its filings.

How fast is Remus Pharmaceuticals Limited growing?

Remus Pharmaceuticals Limited: Latest-half-year revenue is up 30.4% year on year, profit up 21.7%.

How profitable is Remus Pharmaceuticals Limited?

On a trailing-twelve-month basis return on equity is 10.5%, return on capital employed 16.2%, operating margin 6.6%, net margin 4.3%.

How much debt does Remus Pharmaceuticals Limited have?

Remus Pharmaceuticals Limited is lightly geared: debt to equity is 0.07 with borrowings of ₹23 cr against cash of ₹12 cr (balance sheet of 2026-03-31). Operating profit covers interest 41.2 times.

Financials parsed from Remus Pharmaceuticals Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY24, annual from FY24, balance sheet from Sep '24. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.